SSA
ANIK icon

Schonfeld Strategic Advisors’s Anika Therapeutics ANIK Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,021
Closed -$160K – 2584
2026
Q1 		$160K Buy
+11,021
New +$128K ﹤0.01% 1799
2020
Q4 		– Sell
-9,906
Closed -$350K – 1548
2020
Q3 		$350K Buy
+9,906
New +$358K 0.01% 1038
2020
Q2 		– Sell
-10,424
Closed -$301K – 1223
2020
Q1 		$301K Buy
+10,424
New +$422K 0.02% 750
2018
Q3 		– Sell
-11,300
Closed -$361K – 790
2018
Q2 		$361K Buy
+11,300
New +$465K 0.02% 595

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Schonfeld Strategic Advisors's ANIK Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Anika Therapeutics (ANIK) in Q2 2026, closing a stake of 11,021 shares — an estimated $160K sold.

Schonfeld Strategic Advisors first reported a position in ANIK in Q2 2018 and held it in 4 quarters. The position peaked at $361K in Q2 2018. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining Anika Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 11,021 Anika Therapeutics shares in Q2 2026, an estimated $160K.
  • Schonfeld Strategic Advisors first reported a position in Anika Therapeutics in Q2 2018 and held it in 4 quarters.
  • Schonfeld Strategic Advisors's Anika Therapeutics position peaked at $361K in Q2 2018.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.